Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Market price (% of par)
-
112.08%
-
Total 13F principal
-
$265,777,587
-
Principal change
-
+$265,777,587
-
Total reported market value
-
$298,923,677
-
Number of holders
-
27
-
Value change
-
+$298,923,677
-
Number of buys
-
27
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q1 2021
As of 31 Mar 2021,
REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by
27 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$265,777,587
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, FRANKLIN RESOURCES INC, LAZARD ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, PUTNAM INVESTMENTS LLC, MORGAN STANLEY, AMUNDI ASSET MANAGEMENT US, INC., CAPSTONE INVESTMENT ADVISORS, LLC, DeepCurrents Investment Group LLC, and ROYAL BANK OF CANADA.
This page lists
27
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.